Zealand Pharma
Zealand Pharma to present at the J.P. Morgan Healthcare Conference
Zealand Pharma to present at the J.P. Morgan Healthcare Conference
Press release – No. 1 / 2026
Zealand Pharma to present at the J.P. Morgan Healthcare Conference
Copenhagen, Denmark, January 5, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the Company will participate in the 44th J.P. Morgan Healthcare Conference on January 12-15, 2026 in San Francisco, California.
Adam Steensberg, President and Chief Executive Officer, will take part in a presentation and fireside chat on Wednesday January 14 at 1:30pm PST / 10:30pm CET. A live audio webcast will be available at: https://jpmorgan.metameetings.net/events/healthcare26/sessions/317741-zealand-pharma/webcast?gpu_only=true&kiosk=true.
A replay of the webcast will be available at https://www.zealandpharma.com/events/.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.
To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.
Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.
Contacts
Adam Lange (Investors)
Vice President, Investor Relations
Zealand Pharma
Email: alange@zealandpharma.com
Neshat Ahmadi (Investors)
Investor Relations Manager
Zealand Pharma
Email: neahmadi@zealandpharma.com
Rachel James-Owens (Media)
Vice President, Corporate Communications & Media Relations
Zealand Pharma
RJamesOwens@zealandpharma.com
Amber Fennell, Jessica Hodgson, Sean Leous (Media)
ICR Healthcare
ZealandPharma@icrhealthcare.com
+44 (0) 7739 658 783
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Aspo Plc9.1.2026 17:30:00 CET | Press release
Aspo Plc: Share repurchase 9.1.2026
Aalborg Boldspilklub A/S9.1.2026 16:48:49 CET | Pressemeddelelse
Foreslået ændring i bestyrelsen i AaB A/S
Novartis Pharma AG9.1.2026 16:30:00 CET | Press release
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
Sveriges Riksbank9.1.2026 16:20:00 CET | Press release
CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS
Wolters Kluwer N.V.9.1.2026 16:00:00 CET | Press release
Wolters Kluwer appoints Maria Montenegro as CEO of Corporate Performance & ESG division
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom